A double-blind randomised crossover trial of low-dose flumazenil for benzodiazepine withdrawal: A proof of concept

BZDs are often a difficult drug class to cease once neuroadaptation has occurred; recommendations usually involve gradual dose reductions of variable rates. A growing body of evidence has suggested that low dose flumazenil, a GABAA receptor antagonist, may be a useful agent to allow for rapid detoxification.